185 related articles for article (PubMed ID: 8887350)
1. Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.
Nakamura M; Okada H; Sasaki H; Yoshida K; Kamada M; Okada N; Terada M; Ohno T
Microbiol Immunol; 1996; 40(8):561-7. PubMed ID: 8887350
[TBL] [Abstract][Full Text] [Related]
2. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT
J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140
[TBL] [Abstract][Full Text] [Related]
3. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
[TBL] [Abstract][Full Text] [Related]
4. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
5. Isolation and functional assay of the membrane complement inhibitors CD55 (DAF) and CD59 (MIRL).
Parker CJ
Curr Protoc Immunol; 2001 May; Chapter 13():13.5.1-13.5.18. PubMed ID: 18432718
[TBL] [Abstract][Full Text] [Related]
6. Complement activation by human monoclonal antibodies to human immunodeficiency virus.
Spear GT; Takefman DM; Sullivan BL; Landay AL; Zolla-Pazner S
J Virol; 1993 Jan; 67(1):53-9. PubMed ID: 7677959
[TBL] [Abstract][Full Text] [Related]
7. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
8. Complement-dependent virolysis of HIV-1 with monoclonal antibody NM-01.
Nakamura M; Sasaki H; Terada M; Ohno T
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):619-26. PubMed ID: 8369167
[TBL] [Abstract][Full Text] [Related]
9. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers.
Navenot JM; Villanova M; Lucas-Héron B; Malandrini A; Blanchard D; Louboutin JP
Muscle Nerve; 1997 Jan; 20(1):92-6. PubMed ID: 8995588
[TBL] [Abstract][Full Text] [Related]
11. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.
Li Y; Parks GD
Viruses; 2018 Apr; 10(5):. PubMed ID: 29693588
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
[TBL] [Abstract][Full Text] [Related]
14. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
15. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.
Saifuddin M; Ghassemi M; Patki C; Parker CJ; Spear GT
AIDS Res Hum Retroviruses; 1994 Jul; 10(7):829-37. PubMed ID: 7527236
[TBL] [Abstract][Full Text] [Related]
16. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120.
Dianzani U; Bragardo M; Buonfiglio D; Redoglia V; Funaro A; Portoles P; Rojo J; Malavasi F; Pileri A
Eur J Immunol; 1995 May; 25(5):1306-11. PubMed ID: 7539755
[TBL] [Abstract][Full Text] [Related]
18. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
Hu W; Yu Q; Hu N; Byrd D; Amet T; Shikuma C; Shiramizu B; Halperin JA; Qin X
J Immunol; 2010 Jan; 184(1):359-68. PubMed ID: 19955519
[TBL] [Abstract][Full Text] [Related]
19. X-irradiation does not affect the levels of complement regulatory proteins, CD35 (CR1), CD55 (DAF) and CD59 on concentrated red cells.
Fukumori Y; Seya T; Ohnoki S; Shibata H; Yamaguchi H
Vox Sang; 1996; 71(4):243-4. PubMed ID: 8958650
[No Abstract] [Full Text] [Related]
20. Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.
Amet T; Lan J; Shepherd N; Yang K; Byrd D; Xing Y; Yu Q
AIDS Res Hum Retroviruses; 2016; 32(10-11):1100-1112. PubMed ID: 27231035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
